Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans |
| |
| Affiliation: | 1. Department of Surgery, The George Washington University, 2150 Pennsylvania Ave, NW, Suite 6B, 20037, Washington, DC, USA;1. Department of Emergency Medicine, National Taiwan University Medical College and Hospital, Taipei, Taiwan;2. Department of Emergency Medicine, Taipei Hospital, Ministry of Health and Welfare, Taipei, Taiwan;3. Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan;4. Division of Cardiology, Department of Internal Medicine, National Taiwan University Medical College and Hospital, Taipei, Taiwan;5. Department of Emergency Medicine, Lotung Poh-Ai Hospital, Yilan County, Taiwan |
| |
| Abstract: | Dexmedetomidine is a potent and highly selective α2-adrenoceptor agonist with a selectivity ratio of 1600:1 (α2:α1). Dexmedetomidine is a highly lipophylic agent that is rapidly distributed to tissues with a distribution half-life (t1/2α) of approximately 6 minutes. It is extensively distributed and rapidly eliminated, with a mean elimination half-life (t1/2) of 2–2.5 hours. This rapid distribution and short elimination kinetics makes dexmedetomidine amenable to frequent titration allowing adjustability of dosage and effects. Generally, dexmedetomidine does not exhibit pharmacokinetic-based interactions; however, dosage modifications of some concomitant medications may be needed to be adjusted due primarily to common pharmacological actions of the two drugs. Dexmedetomidine is eliminated by metabolism to inactive metabolites, primarily glucuronides. Eighty to ninety percent of an administered dose is excreted in the urine and 5%–13% in the faeces. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
